TY - JOUR
T1 - Two-Phase Synthesis of Taxol
AU - Kanda, Yuzuru
AU - Nakamura, Hugh
AU - Umemiya, Shigenobu
AU - Puthukanoori, Ravi Kumar
AU - Murthy Appala, Venkata Ramana
AU - Gaddamanugu, Gopi Krishna
AU - Paraselli, Bheema Rao
AU - Baran, Phil S.
N1 - Funding Information:
We are especially grateful to Yerram Reddy, V. K. R. and Kokkirala, Y. V. of Chemveda for providing ample quantities of compound 14 . Financial support for this work was provided by NIH (GM-118176), Funai overseas scholarship (predoctoral fellowship to Y.K.), Honjo international scholarship (predoctoral fellowship to Y.K.), and JSPS (postdoctoral fellowship to H.N.). The early stages of this program were funded in part by grants from TEVA, LEO Pharma, Bristol-Myers Squibb, and The Scripps Research Institute. We thank D.-H. Huang and L. Pasternack (Scripps Research Institute) for assistance with NMR spectroscopy; M. Gembicky (University of California, San Diego) for assistance with X-ray crystallography; and J. S. Chen, B. B. Sanchez, and E. Sturgell (Scripps Research Institute) for assistance with LCMS analysis and HRMS analysis. We thank the NOSAMS facility for conducting the isotopic analysis (NSF Cooperative Agreement No. OCE-1239667).
Publisher Copyright:
Copyright © 2020 American Chemical Society.
PY - 2020/6/10
Y1 - 2020/6/10
N2 - Taxol (a brand name for paclitaxel) is widely regarded as among the most famed natural isolates ever discovered, and has been the subject of innumerable studies in both basic and applied science. Its documented success as an anticancer agent, coupled with early concerns over supply, stimulated a furious worldwide effort from chemists to provide a solution for its preparation through total synthesis. Those pioneering studies proved the feasibility of retrosynthetically guided access to synthetic Taxol, albeit in minute quantities and with enormous effort. In practice, all medicinal chemistry efforts and eventual commercialization have relied upon natural (plant material) or biosynthetically derived (synthetic biology) supplies. Here we show how a complementary divergent synthetic approach that is holistically patterned off of biosynthetic machinery for terpene synthesis can be used to arrive at Taxol.
AB - Taxol (a brand name for paclitaxel) is widely regarded as among the most famed natural isolates ever discovered, and has been the subject of innumerable studies in both basic and applied science. Its documented success as an anticancer agent, coupled with early concerns over supply, stimulated a furious worldwide effort from chemists to provide a solution for its preparation through total synthesis. Those pioneering studies proved the feasibility of retrosynthetically guided access to synthetic Taxol, albeit in minute quantities and with enormous effort. In practice, all medicinal chemistry efforts and eventual commercialization have relied upon natural (plant material) or biosynthetically derived (synthetic biology) supplies. Here we show how a complementary divergent synthetic approach that is holistically patterned off of biosynthetic machinery for terpene synthesis can be used to arrive at Taxol.
UR - http://www.scopus.com/inward/record.url?scp=85086356213&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086356213&partnerID=8YFLogxK
U2 - 10.1021/jacs.0c03592
DO - 10.1021/jacs.0c03592
M3 - Article
C2 - 32406238
AN - SCOPUS:85086356213
SN - 0002-7863
VL - 142
SP - 10526
EP - 10533
JO - Journal of the American Chemical Society
JF - Journal of the American Chemical Society
IS - 23
ER -